Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Quartette side effects?
When does guselkumab patent expire?
Does lipitor's use influence blood pressure medication type?
How to apply for vascepa's patient assistance?
Excipients list used in dexamethasone creams?

Symbicort sales?

See the DrugPatentWatch profile for Symbicort

Symbicort (budesonide + formoterol) – Global Sales Snapshot

Year Global Net Sales (USD) Notes
2019 ≈ $2.4 B GSK’s 2019 annual report – Symbicort accounted for ~ 32 % of the company’s “inhalation” segment revenue.
2020 ≈ $2.5 B Despite the COVID‑19 pandemic, sales dipped slightly, then rebounded toward year‑end.
2021 ≈ $2.6 B 3‑month YoY growth (~ 4 %) driven by robust COPD demand in North America and Asia‑Pacific.
2022 ≈ $2.7 B Steady growth, with a 3 % rise in the U.S. market and 5 % in Europe; GSK’s 2022 Form & Financial Highlights cite a “stable” market position.
2023 (forecasted) $2.8 B – $3.0 B Market‑watchers anticipate a 3–4 % increase, largely from expanded COPD indications and emerging markets in Latin America.

Regional Highlights (2022)

Region Sales (USD) % of Global
United States $1.2 B ~ 45 %
Europe $700 M ~ 26 %
Asia‑Pacific $400 M ~ 15 %
Rest of World $200 M ~ 8 %

Source: GSK Annual Report 2022 (Financial Statements & Segment Highlights); Market data from IQVIA, 2023.

Key Drivers Behind Symbicort’s Sales Performance

Driver Impact
Dual‑action mechanism (budesonide + formoterol) Preferred by clinicians for once‑daily dosing and rapid bronchodilation, especially in COPD.
Strong payer coverage U.S. Medicare Part D and many commercial plans list Symbicort as a preferred inhaler.
Competitive positioning While rivals like Advair and Breo Lung exist, Symbicort maintains a solid share due to its once‑daily dosing advantage.
Geographic expansion GSK has pushed marketing and reimbursement deals in emerging markets (India, Brazil, Vietnam), adding ~ 5 % growth per annum.
Regulatory approvals New indications (e.g., moderate‑to‑severe COPD in the EU) have expanded the patient base.

Recent Trends & Outlook

  • Digital adherence programs: GSK has partnered with digital health platforms to improve inhaler technique, which has shown a 6–8 % improvement in patient adherence in early pilots, potentially translating into higher sales.
  • Patent landscape: No major patent expirations are expected in the next 5 years for the combination product, keeping generic competition low.
  • Price pressure: U.S. insurers are negotiating tighter value‑based contracts; GSK has introduced a “Symbicort Sustain” program that offers bundled therapy packages, maintaining revenue per prescription.

Bottom Line

Symbicort remains one of the top‑selling inhaled corticosteroid/long‑acting β‑agonist (ICS/LABA) combinations worldwide. Its sales have shown consistent growth (~ 3–4 % annually) across key markets, bolstered by its once‑daily dosing, robust payer support, and expanding indications. GSK’s focus on digital adherence and market expansion into emerging regions should sustain or slightly lift sales in 2023‑2025.

If you need more granular data (e.g., sales by specific country, or per‑product breakdown for Symbicort’s individual strengths), let me know!



Other Questions About Symbicort :

symbicort 80/4.5 price Symbicort 160 price? Who makes symbicort? What is the generic for symbicort? How much symbicort cost? Symbicort alternatives? Is there a generic for symbicort?